Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
These medicines have not been approved for use in people with Type 1 diabetes, although researchers are currently studying the safety and effectiveness for people with Type 1
de Mesquita FC, Guixe-Muntet S, Fernandez-Iglesias A, Maeso-Diaz R, Vila S, Hide D, et al
These are usually worse after high-fat meals and tend to settle if you reduce the amount of fat in your diet
Early treatment weeks are often focused on helping your body adjust rather than maximizing weight loss
Limitations: - CT-388 data is early stage (Phase 1/2), making comparisons to late-stage or approved competitors regarding efficacy somewhat premature.- Competitor trials involving semaglutide and tirzepatide are based on larger patient populations and longer duration, providing a more robust data set validating their therapeutic benefit.- Weight loss achieved with GLP-1 receptor agonists such as semaglutide and the dual GLP-1/GIP receptor agonist tirzepatide appear greater than the weight loss observed to date with CT-388.- Competitor agents have established cardiovascular benefits and substantial net weight reductions, which set a high efficacy bar for CT-388 to meet or exceed.- Incretin therapies are challenged by supply shortages and complex titration schemes
- Improved libido and sleep quality
